SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT)

SBHW-PREDICT（蛋白质组学、遗传学和 CT 定向成像的作用）

• 批准号: 9109508
• 负责人: Shaista Malik
• 金额: $ 69.45万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-15 至 2020-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9109508
• 关键词: Address; Biological; Biological Markers; Blood Tests; Calcium; Cardiac; Cardiovascular system; Cells; Cessation of life; Chemotaxis; Clinical; Coronary; Coronary artery; Coronary heart disease; Data; Discrimination; Disease; Early treatment; Eotaxin; Event; Family; Family history of; Fibrosis; Freezing; Funding; Genetic; Genetic Markers; Genetic Predisposition to Disease; Genetic Risk; Genetic screening method; Health; Heart; Heart Diseases; Homeostasis; Image; Imaging Device; Incidence; Individual; Inflammation; Interdisciplinary Study; Interleukin-6; Medicare; Medicare claim; Myocardial Infarction; Outcome; Participant; Pathway interactions; Phenotype; Plasma; Plasma Cells; Population; Predictive Value; Predisposition; Prevention; Proteomics; Recording of previous events; Research; Risk; Risk Assessment; Risk Factors; Role; Sampling; Serum; Signal Transduction; Stable Disease; Stress; Survivors; Testing; Time; Troponin; United States National Institutes of Health; Vascular calcification; X-Ray Computed Tomography; adiponectin; alpha-Fetoproteins; base; circulating biomarkers; cohort; density; experience; follow-up; genetic profiling; heart disease risk; imaging biomarker; improved; indexing; lipoprotein-associated phospholipase A(2); mortality; non-invasive imaging; novel marker; premature; prevent; prognostic value; screening

 DESCRIPTION (provided by applicant): In our proposed study, SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT), we will assess whether identification of at-risk individuals, using imaging markers, a biomarker profile or a combination of the two, improves reclassification and discrimination over traditional risk factors, particularly in those wth either a family history of coronary heart disease (CHD) or higher genetic predisposition for CHD. We have used data from 1312 participants of the first NIH-funded study of predictive value of CAC, the South Bay Heart Watch (SBHW) study, to calculate plaque density. In preliminary analyses, we have found that higher plaque density is related to lower incidence of CVD events in this cohort. In the proposed study, we will use serum and cell samples collected at baseline, 20 years ago, from the SBHW and retrospectively assess outcomes using administrative data from Medicare and the National Death Index to address the following aims and objectives: 1) Using Medicare Claims and National Death Index data assess prognostic value of baseline CAC, as well as coronary calcium density for long-term (20 year) CHD event rate; 2) Using serum and cell samples collected at baseline, assess whether a multi-biomarker approach using circulating markers from different biological pathways would have additional reclassification value over traditional risk factors; 3) Determine whether compared to family history a CHD genetic risk score is more predictive of events; and 4) Determine whether a genetic score modifies the prognostic value of an imaging marker (CAC) or a multiple biomarker score or a combination of the two in those at higher predisposition (based on either family history or genetic score) for CHD versus those at low genetic risk. The experience of our multidisciplinary research team, unique 20 year follow-up period after baseline CAC, linkage to Medicare claims data and Death Index data, genetic and biomarker profiles using frozen serum and cell samples, and follow-up of the original cohort survivors are major strengths of this proposal. Results of thi project will assess the utility of a complementary genetic marker, multi-biomarker, and imaging approach to risk assessment.

 描述（由适用提供）：在我们提出的研究中，SBHW预测（蛋白质组学，遗传学和使用CT的成像的作用），我们将评估是否使用成像标记，生物标记物的概况，生物标记物的概况，两者的组合，在传统的风险因素上，尤其是遗传因素，尤其是遗传因素，尤其是coron的疾病（coron），是coron的疾病（coron），是coron的疾病，是coron史（coron）的疾病，是coron的疾病（cor），是coron的疾病，是coron史（coron）的疾病（cor），是coron的病史（coron）的疾病，是coron的疾病史（cor）。冠心。我们已经使用了1312名参与者的数据，其中首次由NIH资助的CAC（SBHW）研究（SBHW）研究的预测价值研究来计算斑块密度。在初步分析中，我们发现较高的斑块密度与该队列中CVD事件的较低入射有关。在拟议的研究中，我们将使用SBHW和回顾性地评估结果的基线血清和细胞样本，并使用来自Medicare和国家死亡指数的管理数据来评估结果，以解决以下目的和目标：1）使用Medicare索赔和国家死亡指数数据评估评估基线CAC的预后价值（以及基线速度的速度），以及20年级的速率（20年），供应率（20年）。 2）使用在基线时收集的血清和细胞样品，评估使用来自不同生物学途径的循环标记的多生物标志物方法是否会比传统风险因素具有额外的重新分类值； 3）确定与家族史相比，冠心病遗传风险评分更能预测事件； 4）确定遗传评分是否会修改成像标记（CAC）的预后价值，或多个生物标志物评分，还是在较高的易感性（基于家族病史或遗传评分）中的两者组合的组合（基于CHD的家族病史或遗传评分），而与低遗传风险的人相比。我们的多学科研究团队的经验，基线CAC之后的独特的20年随访期，与Medicare索赔数据和死亡指数数据的联系，使用冷冻血清和细胞样本的遗传和生物标志物概况以及原始同队生存的随访是该提议的主要优势。 THI项目的结果将评估完整的遗传标记，多生物标记和风险评估成像方法的效用。